MDT-AP-1108
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 144.96
- os_event
- false
- age_years
- 6.8
- sex
- M
- new_clusters
- C4
- umap1_2d
- 4.201681073
- umap2_2d
- 4.89517771
- umap1_3d
- 1.078748721
- umap2_3d
- -0.137550851
- umap3_3d
- -0.846486162
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.600
- INFLAMMATORY_RESPONSE+0.510
- ANGIOGENESIS+0.490
- KRAS_SIGNALING_UP+0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- KRAS_SIGNALING_DN+0.410
- ALLOGRAFT_REJECTION+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INTERFERON_GAMMA_RESPONSE+0.390
- COAGULATION+0.380
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.620
- MYC_TARGETS_V2-0.610
- MYC_TARGETS_V1-0.600
- E2F_TARGETS-0.510
- PROTEIN_SECRETION-0.500
- G2M_CHECKPOINT-0.460
- MITOTIC_SPINDLE-0.460
- DNA_REPAIR-0.450
- ADIPOGENESIS-0.420
- UNFOLDED_PROTEIN_RESPONSE-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1352706 | GTEX | — | 0.964 |
| 2 | BS_YG0A13JH | pilocytic astrocytoma | — | 0.959 |
| 3 | sclcA055A_S52.txt | — | cohortMD2 | 0.955 |
| 4 | SRR1414424 | GTEX | — | 0.951 |
| 5 | SRR1467294 | GTEX | — | 0.951 |
| 6 | BS_B0SVFK4P | pleomorphic xanthoastrocytoma(PXA) | — | 0.949 |
| 7 | SRR818469 | GTEX | — | 0.947 |
| 8 | SRR1500800 | GTEX | — | 0.946 |
| 9 | BS_2SHWPB5P | ganglioneuroblastoma | — | 0.945 |
| 10 | BS_ZTWGFWTX | pilocytic astrocytoma | — | 0.945 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.600 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.440 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.410 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| APOPTOSIS | 0.330 | Idelalisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.320 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |